All In MedTech

FDA Clearance Tracker · P240011-S004

Medtronic Altaviva System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 19, 2025

Approved

Time to decision

28 days

Received Nov 21, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P240011-S004
Device name
Medtronic Altaviva System
Applicant location
Minneapolis, MN
Received
Nov 21, 2025
Decided
Dec 19, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P240011

Device type

Device class
Class III

Every decision under product code QPT

FDA's approval statement

As written in FDA's record.

The protocol modifications include the addition of quality-of-life, work productivity, mental health, and sexual health questionnaires. Additional revisions included changing "up to 30 institutions" to "approximately 30 institutions", requirements for appropriate investigator training, education, and experience, and updated language regarding the 6-month washout period for botulinum toxin therapy and sacral neuromodulation.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.